The type III TGF-β receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-β signaling

Jason D. Lee, Nadine Hempel, Nam Y. Lee, Gerard C. Blobe

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Loss of expression of the type III transforming growth factor-β receptor (TβRIII or betaglycan), a transforming growth factor-β (TGF-β) superfamily co-receptor, is common in human breast cancers. TβRIII suppresses cancer progression in vivo by reducing cancer cell migration and invasion by largely unknown mechanisms. Here, we demonstrate that the cytoplasmic domain of TβRIII is essential for TβRIII-mediated downregulation of migration and invasion in vitro and TβRIII-mediated inhibition of breast cancer progression in vivo. Functionally, the cytoplasmic domain of TβRIII is required to attenuate TGF-β signaling, whereas TβRIII-mediated attenuation of TGF-β signaling is required for TβRIII-mediated inhibition of migration and invasion. Mechanistically, both TbRIII-mediated inhibition of TGF-β signaling and TβRIII-mediated inhibition of invasion occur through the interaction of the cytoplasmic domain of TβRIII with the scaffolding protein GAIP-interacting protein C-terminus (GIPC). Taken together, these studies support a functional role for the TβRIII cytoplasmic domain interacting with GIPC to suppress breast cancer progression.

Original languageEnglish (US)
Article numberbgp271
Pages (from-to)175-183
Number of pages9
JournalCarcinogenesis
Volume31
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'The type III TGF-β receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-β signaling'. Together they form a unique fingerprint.

  • Cite this